Should the one-stage hepatectomy be performed for hepatitis B virus-related hepatocellular carcinoma patients with liver fibrosis or cirrhosis when the RLV/SLV is between 30% to 40%?

Author:

Gao Junping1,Yang Haojie1,Lu Zhan1,Zhan Guohua1,Huang Juntao1,Gong Wenfeng1,xiang bangde1

Affiliation:

1. Guangxi Medical University Cancer Hospital, Guangxi Zhuang Autonomous Region

Abstract

Abstract

Background Currently, it is known whether associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) or one-stage hepatectomy (OSH) be applied as a treatment for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients with liver fibrosis or cirrhosis when the remnant liver volume (RLV) to standard liver volume (SLV) ratio is between 30–40% and the liver function is normal. Methods In this study, consecutive HBV-related HCC patients with liver fibrosis or cirrhosis who underwent right hepatectomy, with RLV/SLV between 30–40% and normal liver function (Child-pugh A and ICG-R15 < 10%) were enrolled from November 2014 to November 2022. The clinical datas of patients were recorded. Primary endpoints was post-hepatectomy liver failure (PHLF), while secondary endpoints were severe complication and mortality. The postoperative datas of patients were compared between OSH group and ALPPS group. Results Forty-two patients who underwent OSH were enrolled in our study. No significant difference was obtained in the incidence of PHLF between the OSH group (59.5%) and the ALPPS group (52.3%) (P = 0.411). The mortality within 90 days of the OSH group (0%) post-surgery was significantly lower compared with that of the ALPPS group (13.2%) (P = 0.006). Moreover, there was no significant difference in the incidence of severe complication (Clavien-Dindo classification ≥Ⅲa) between the OSH group (26.2%) and the ALPPS group (36.8%) (P = 0.199). Conclusion OSH may be an effective treatment option for patients with liver fibrosis or cirrhosis when the RLV/SLV is between 30–40% with normal liver function (Child-pugh A and ICG-R15 < 10%).

Publisher

Springer Science and Business Media LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3